NCT05396235已完成1 期
A Clinical Pharmacology Study of MT-3921 in Healthy Adult Males
适应症
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 10
- 试验地点
- 2
- 主要终点
- Time course of serum concentrations of MT-3921
研究概览
简要总结
The purpose of this study is to investigate the safety, tolerability, and pharmacokinetics when MT-3921 or a placebo is intravenously given to Japanese healthy adult male subjects
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Other
- 盲法
- Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
入排标准
- 年龄范围
- 18 Years 至 55 Years（Adult）
- 性别
- Male
- 接受健康志愿者
- 是
入选标准
- •Additional screening criteria check may apply for qualification:
- •Japanese healthy adult males
- •Subjects aged between 18 and 55 years inclusive at the time of informed consent
- •Subjects with a full understanding of the nature of this study who have consented in writing to participate in the study
排除标准
- •Additional screening criteria check may apply for qualification:
- •Subjects with or having a history or treatment history of disorders, including cardiac, hepatic, renal, gastrointestinal, respiratory, neuropsychiatric, hematopoietic, or endocrine system disorder, who are judged by the investigator (or subinvestigator) to be unfit for study participation
- •Subjects with a history of drug or food allergies, including anaphylaxis or significant allergic reactions
- •Subjects with a body mass index (BMI) of less than 18.5 kg/m^2 or greater than 25 kg/m^2 at the time of screening or Day -1 or those with a body weight of less than 50 kg or greater than 80 kg
- •Subjects who have donated blood or from whom blood samples have been collected in a total amount of 400 mL or more within 12 weeks prior to informed consent, 200 mL or more within 4 weeks prior to informed consent, or 800 mL or more within 1 year prior to informed consent
- •Subjects who have donated blood component or platelet apheresis within 2 weeks prior to informed consent
- •Subjects with or having a history of drug dependence or alcohol dependence
- •Subjects with clinically significant abnormalities on a 12-lead ECG, with a Fridericia-corrected QT (QTcF) interval of ≥450 msec, or with clinically significant abnormalities on an auscultation
- •Subjects with a positive result for hepatitis B virus surface (HBs) antigen, serological test for syphilis, hepatitis C virus (HCV) antibody, or human immunodeficiency virus (HIV) antigen/antibody at screening
- •Subjects with a positive polymerase chain reaction (PCR) test for Coronavirus disease 2019 (COVID-19)
- •Subjects with a family history of sudden death
- •Subjects who answered "yes" to any of the items of suicide ideation or suicide attempts in the Columbia Suicide Rating Scale (C-SSRS) assessment in the screening period
- •Subjects who do not agree to practice contraception during the study period
- •Subjects who have previously received anti-RGMa antibodies, including this investigational product
- •Subjects who have participated in other clinical studies and received other investigational products within 12 weeks before informed consent
- •Subjects who have used any drug other than the investigational product in the period within 7 days before the start of investigational product administration or 5 times the half-life of the drug, whichever is longer
结局指标
主要结局
Time course of serum concentrations of MT-3921
时间窗: Day 1, 2, 3, 4, 8, 15, 29, 57, 85, and 113.
Percentage of subjects with adverse events
时间窗: 16 weeks
Percentage of subjects with adverse reactions
时间窗: 16 weeks
次要结局
未报告次要终点
研究者
研究点 (2)
Loading locations...
相似试验
已完成
1 期
Safety and Pharmacokinetics Study of MT-3921 in Spinal Cord InjurySpinal Cord InjuryNCT04096950Mitsubishi Tanabe Pharma America Inc.3
已完成
1 期
A Clinical Pharmacological Study of MT-3921 in Subjects With HTLV-1 Associated Myelopathy (HAM)HTLV-1-Associated Myelopathy (HAM)NCT05240612Mitsubishi Tanabe Pharma Corporation15
已完成
1 期
A Clinical Pharmacology Study of MT-3921 in Healthy Adult MalesAcute Traumatic Cervical Spinal Cord Injury, HTLV-1-Associated Myelopathy (HAM)JPRN-jRCT2031220182Kondo Kazuoki10
已完成
1 期
A Clinical Pharmacological Study of MT-3921 in Subjects with HAMHuman T-cell Leukemia Virus Type 1 (HTLV-1)-Associated Myelopathy (HAM)JPRN-jRCT2031210616Kazuoki Kondou15
已完成
1 期
A Clinical Pharmacology Study of MT-2990 in Seasonal Allergic Rhinitis PatientsSeasonal Allergic RhinitisNCT03570957Tanabe Pharma Corporation75